Newlink Genetics reported 3.62M in Selling and Administration Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Agenus AGEN:US $ 18.95M 3.02M
Bristol Myers Squibb BMY:US $ 1.83B 523M
Capricor Therapeutics CAPR:US 2.72M 599.73K
Celldex Therapeutics CLDX:US $ 6.91M 670K
Eli Lilly And LLY:US $ 1.56B 34.1M
Idera Pharmaceuticals IDRA:US $ 2.4M 381K
Intrexon XON:US $ 19.58M 2.81M
Merk MRK:US $ 2.3B 518M
Nektar Therapeutics NKTR:US $ 27.34M 4.8M
Newlink Genetics NLNK:US 3.62M 193K
Prothena PRTA:US 11.84M 371K
Sarepta Therapeutics SRPT:US $ 71.84M 6.22M
Vascular Biogenics VBLT:US 3.16M 237K
YTE INCY:US $ 209.58M 16.62M